{"title":"活体肾移植受者BK多瘤病毒肾病的患病率和预后","authors":"Abhyudaysingh Rana, Shyam Bihari Bansal, Camille Nelson Kotton, Amit Kumar Mahapatra, Alka Rana, Sidharth Kumar Sethi, Pranaw Kumar Jha, Ashwini B Gadde, Manish Jain, Dinesh Kumar Yadav, Dinesh Bansal, Vijay Kher","doi":"10.25259/ijn_87_23","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>BK polyomavirus nephropathy (BKPyVN) remains an important cause of allograft dysfunction and loss. There is little data about prevalence and outcome of BKPyVN infection from India in living donor kidney transplant recipients.</p><p><strong>Materials and methods: </strong>This is a retrospective analysis of all biopsy-proven BKPyVN among kidney transplant recipients at our center from January 2010 to January 2022. We compared them to age, sex, and type of immunosuppression received matched (1:2) non-BKPyVN-infected recipients transplanted during the same period.</p><p><strong>Results: </strong>During the study period, 2465 patients underwent kidney transplants at our center, of which 26 (1.05%) developed biopsy-proven BKPyVN. Four recipients (16%) lost their graft over a median period of 65 (IQR, 57-83) months from the time of diagnosis. The mean serum creatinine at the recent follow-up was higher in the BKPyVN arm as compared to controls (2.05 ± 1.39 vs 1.35 ± 0.46, p = 0.001.) Both BKPyVN and control arms had similar death-censored graft survival (82% vs 94%, p = 0.09) and patient survival (88% vs 96%, p = 0.184).</p><p><strong>Conclusion: </strong>BKPyVN was uncommon in our kidney transplant recipients. Most patients were able to maintain their kidney function for many years, albeit at a somewhat reduced level compared with the controls, and about a fifth of our patients lost their graft.</p>","PeriodicalId":13359,"journal":{"name":"Indian Journal of Nephrology","volume":"35 3","pages":"343-348"},"PeriodicalIF":0.8000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12065578/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Prevalence and Outcomes of BK Polyoma Virus Nephropathy in Living Donor Kidney Transplant Recipients.\",\"authors\":\"Abhyudaysingh Rana, Shyam Bihari Bansal, Camille Nelson Kotton, Amit Kumar Mahapatra, Alka Rana, Sidharth Kumar Sethi, Pranaw Kumar Jha, Ashwini B Gadde, Manish Jain, Dinesh Kumar Yadav, Dinesh Bansal, Vijay Kher\",\"doi\":\"10.25259/ijn_87_23\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>BK polyomavirus nephropathy (BKPyVN) remains an important cause of allograft dysfunction and loss. There is little data about prevalence and outcome of BKPyVN infection from India in living donor kidney transplant recipients.</p><p><strong>Materials and methods: </strong>This is a retrospective analysis of all biopsy-proven BKPyVN among kidney transplant recipients at our center from January 2010 to January 2022. We compared them to age, sex, and type of immunosuppression received matched (1:2) non-BKPyVN-infected recipients transplanted during the same period.</p><p><strong>Results: </strong>During the study period, 2465 patients underwent kidney transplants at our center, of which 26 (1.05%) developed biopsy-proven BKPyVN. Four recipients (16%) lost their graft over a median period of 65 (IQR, 57-83) months from the time of diagnosis. The mean serum creatinine at the recent follow-up was higher in the BKPyVN arm as compared to controls (2.05 ± 1.39 vs 1.35 ± 0.46, p = 0.001.) Both BKPyVN and control arms had similar death-censored graft survival (82% vs 94%, p = 0.09) and patient survival (88% vs 96%, p = 0.184).</p><p><strong>Conclusion: </strong>BKPyVN was uncommon in our kidney transplant recipients. Most patients were able to maintain their kidney function for many years, albeit at a somewhat reduced level compared with the controls, and about a fifth of our patients lost their graft.</p>\",\"PeriodicalId\":13359,\"journal\":{\"name\":\"Indian Journal of Nephrology\",\"volume\":\"35 3\",\"pages\":\"343-348\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12065578/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Journal of Nephrology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.25259/ijn_87_23\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/8/1 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Nephrology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25259/ijn_87_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/1 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:BK多瘤病毒肾病(BKPyVN)仍然是同种异体移植物功能障碍和损失的重要原因。关于印度活体肾移植受者BKPyVN感染的流行率和结果的数据很少。材料和方法:回顾性分析2010年1月至2022年1月在我中心所有肾移植受者活检证实的BKPyVN。我们将他们与同一时期接受匹配(1:2)非bkpyvn感染移植的免疫抑制受体的年龄、性别和类型进行比较。结果:研究期间,本中心共2465例患者行肾移植手术,其中26例(1.05%)发生活检证实的BKPyVN。4名受者(16%)在确诊后的中位65个月(IQR, 57-83个月)内失去移植物。近期随访时,BKPyVN组的平均血清肌酐高于对照组(2.05±1.39 vs 1.35±0.46,p = 0.001)。BKPyVN组和对照组具有相似的死亡审查移植存活率(82%对94%,p = 0.09)和患者生存率(88%对96%,p = 0.184)。结论:BKPyVN在肾移植受者中少见。大多数患者能够维持他们的肾脏功能多年,尽管与对照组相比水平有所降低,大约五分之一的患者失去了移植物。
The Prevalence and Outcomes of BK Polyoma Virus Nephropathy in Living Donor Kidney Transplant Recipients.
Background: BK polyomavirus nephropathy (BKPyVN) remains an important cause of allograft dysfunction and loss. There is little data about prevalence and outcome of BKPyVN infection from India in living donor kidney transplant recipients.
Materials and methods: This is a retrospective analysis of all biopsy-proven BKPyVN among kidney transplant recipients at our center from January 2010 to January 2022. We compared them to age, sex, and type of immunosuppression received matched (1:2) non-BKPyVN-infected recipients transplanted during the same period.
Results: During the study period, 2465 patients underwent kidney transplants at our center, of which 26 (1.05%) developed biopsy-proven BKPyVN. Four recipients (16%) lost their graft over a median period of 65 (IQR, 57-83) months from the time of diagnosis. The mean serum creatinine at the recent follow-up was higher in the BKPyVN arm as compared to controls (2.05 ± 1.39 vs 1.35 ± 0.46, p = 0.001.) Both BKPyVN and control arms had similar death-censored graft survival (82% vs 94%, p = 0.09) and patient survival (88% vs 96%, p = 0.184).
Conclusion: BKPyVN was uncommon in our kidney transplant recipients. Most patients were able to maintain their kidney function for many years, albeit at a somewhat reduced level compared with the controls, and about a fifth of our patients lost their graft.